AUS
NZ
UK
CA
USA
IND
Highlights
- Immuron continues expanding its digestive health product portfolio across multiple markets.
- Travelan® remains a key product supporting digestive tract protection activities.
- ProIBS® forms part of Immuron’s digestive health offering in Australia.
- Immuron’s 3QFY26 quarterly global sales revenue totalled A$1.5 million, up 16% on the prior corresponding period.
Immuron Limited (ASX:IMC) (NASDAQ:IMRN) has continued to expand its presence in the digestive health market through growing sales, commercialisation activities, and portfolio expansion initiatives. With a focus on gastrointestinal health and immune-based therapies, the company markets products targeting travellers' diarrhoea and irritable bowel syndrome (IBS).
As digestive health concerns continue affecting millions globally, Immuron’s activities remain centred on developing and distributing orally delivered products designed to address gastrointestinal conditions and related symptoms.
Focus on Digestive Health
Immuron is an Australian biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the prevention and treatment of infectious diseases and gastrointestinal conditions. The company’s portfolio includes products aimed at digestive health protection and symptom management.
One of Immuron’s key commercial products is Travelan®, an orally administered passive immunotherapy developed to reduce the likelihood of contracting travellers’ diarrhoea. The digestive tract disorder is commonly linked to exposure to pathogenic bacteria and bacterial toxins encountered during travel.
Travelan® contains highly purified hyperimmune bovine antibodies that bind to diarrhoea-causing bacteria when taken with meals. The product is designed to help prevent bacterial colonisation associated with travellers’ diarrhoea.
The product is available across several markets under different classifications. In Australia, Travelan® is listed on the Australian Register for Therapeutic Goods and is indicated to reduce the risk of travellers’ diarrhoea and minor gastrointestinal disorders. In Canada, it is licensed as a natural health product, while in the United States, it is sold as a dietary supplement for digestive tract protection.
ProIBS® Expands Digestive Health Portfolio
Alongside Travelan®, Immuron distributes ProIBS® in Australia under an exclusive agreement with Calmino group AB. The product forms part of the company’s broader digestive health portfolio targeting gastrointestinal conditions.
ProIBS® is an EU certified medical device developed for the treatment of IBS symptoms, including abdominal pain, bloating, diarrhoea, constipation, and unsettled bowel movements. In Australia, ProIBS® is a Listed Medicine. The product contains AVH200® with gel-forming components designed to support the intestinal mucosal barrier.
IBS is a common digestive condition associated with symptoms linked to diet, stress, lifestyle habits, and mood. According to Immuron, around three out of every ten people are affected by IBS, with females more likely to experience the condition.
Calmino group AB conducted a usability study involving 1,003 users of ProIBS®. According to the study results, 94% of users found the product helpful, while 91% reported improvements in daily life and 98% stated they would recommend the product to others.
The broader market opportunity remains significant. According to market data referenced by Immuron, the digestive and intestinal remedies market in Australia is estimated to generate revenue of approximately AU$221.14 million in 2025.
Sales Activities Across Markets
Immuron reported continued sales activity growth during 3Q FY26 across its operating markets. Quarterly global sales revenue totalled A$1.5 million, up 16% on the prior corresponding period. Australian sales increased 15% to A$0.9 million, while Canada sales rose more than 100% to A$0.1 million.
In the United States, sales reached A$0.5 million, reflecting a 1% increase in Australian dollar terms; 13% in US dollar terms.
As it continues expanding commercial activities and growing sales across multiple markets, Immuron remains focused on building its digestive health portfolio while leveraging its existing distribution channels and product offerings to support future growth opportunities.
Shares of IMC traded at AUD 0.047, up 17.5%, on 1 June 2026. In the last one month, the stock has gained 56.67%.
